These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30979743)

  • 1. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
    Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
    Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
    Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
    [No Abstract]   [Full Text] [Related]  

  • 5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
    Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
    Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
    Mondal SK; Basak B; Bhattacharya S; Panda UK
    J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
    Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
    J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
    Rajendran S; McCluggage WG
    Int J Gynecol Pathol; 2022 Mar; 41(2):191-202. PubMed ID: 33782345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 13. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.
    Köbel M; Rahimi K; Rambau PF; Naugler C; Le Page C; Meunier L; de Ladurantaye M; Lee S; Leung S; Goode EL; Ramus SJ; Carlson JW; Li X; Ewanowich CA; Kelemen LE; Vanderhyden B; Provencher D; Huntsman D; Lee CH; Gilks CB; Mes Masson AM
    Int J Gynecol Pathol; 2016 Sep; 35(5):430-41. PubMed ID: 26974996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Köbel M; Yang RZ; Kang EY; Al-Shamma Z; Cook LS; Kinloch M; Carey MS; Hopkins L; Nelson GS; McManus KJ; Vizeacoumar FS; Vizeacoumar FJ; Freywald A; Fu Y; Reuss DE; Lee CH
    Gynecol Oncol; 2023 Nov; 178():80-88. PubMed ID: 37820398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian cancer--modern approach to its origin and histogenesis].
    Nowak-Markwitz E; Spaczyński M
    Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
    Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
    Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
    Al-Hussaini M; Stockman A; Foster H; McCluggage WG
    Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.